Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
ValiRx said its VAL401 anti-cancer compound had a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer
Cereal Ingredients Inc will incorporate SlimBiome into their range of cereal and protein-based particulates which are used in food products such as cakes, cookies and crackers
In the dose expansion phase of its DREAMM-1 phase I/II study of GSK2857916, the antibody-drug conjugate demonstrated a 60% response rate and median progression-free survival of 7.9 months
Allergy already has injectable vaccines for dust mites and tree and grass pollen, but it has brought in Ergomed to take the tablet formulations through clinical trials
The FTSE 250 drugmaker said the acceptance is a “significant milestone” for the treatment
Analysts at the heavyweight bank think Bluebird is making good progress with its cancer and sickle cell disease treatment, while they also consider the firm to be an attractive takeover target
300 patients have now been recruited across Europe for the trial which is looking at whether Traumakine can reduce all-cause mortality in acute respiratory distress syndrome sufferers
Silence bought a 9.2% stake in Arrowhead in January and has started to sell off shares given the rise of Arrowhead’s stock over the past few months
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now